Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma

  • Yoshihiro Nishiyama
  • Yuka Yamamoto
  • Toshihide Monden
  • Yasuhiro Sasakawa
  • Nobuyuki Kawai
  • Katashi Satoh
  • Motoomi Ohkawa
Original article



The purpose of this study was to investigate the accumulation of FDG in immunocompetent patients with primary central nervous system (CNS) lymphoma using qualitative and quantitative PET images and to compare baseline with follow-up PET after therapy.


Twelve immunocompetent patients with CNS lymphoma were examined. Dynamic emission data were acquired for 60 min immediately following injection of FDG. In seven patients, repeated PET studies were performed after treatment. Applying a three-compartment five-parameter model, K1, k2, k3, k4, vascular fraction (VB) and cerebral metabolic rate of glucose (CMRGlc) were obtained. We evaluated the FDG uptake visually using qualitative and parametric images and quantitatively using parametric images.


A total of 12 lesions were identified in ten patients with newly diagnosed CNS lymphoma. On visual analysis, ten lesions showed an increase on qualitative images, eight showed an increase on K1 images, 12 showed an increase on k3 images and ten showed an increase on CMRGlc images. On quantitative analysis, k2, k3 and CMRGlc values of the lesion were significantly different from those of the normal grey matter (p<0.02–0.0005). A total of three lesions were identified in two patients with recurrent tumour. All three lesions showed an increase on qualitative, k3 and CMRGlc images. The K1, k2, k3 and CMRGlc values after treatment were significantly different from those obtained before treatment (p<0.04–0.008).


Kinetic analysis, especially with respect to k3, using dynamic FDG PET might be helpful for diagnosis of CNS lymphoma and for monitoring therapeutic assessment.


FDG PET Kinetic modelling Brain tumour Lymphoma Neurology 


  1. 1.
    Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988;68:835–854PubMedCrossRefGoogle Scholar
  2. 2.
    Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323–331PubMedCrossRefGoogle Scholar
  3. 3.
    Jiddane M, Nicoli F, Diaz P, Bergvall U, Vincentelli F, Hassoun J, et al. Intracranial malignant lymphoma: report of 30 cases and review of the literature. J Neurosurg 1986;65:592–599PubMedGoogle Scholar
  4. 4.
    Basso U, Brandes AA. Diagnostic advances and new trends for treatment of primary central nervous system lymphoma. Eur J Cancer 2002;38:1298–1312PubMedCrossRefGoogle Scholar
  5. 5.
    Coleman RE. Clinical PET in oncology. Clin Pos Imaging 1998;1:15–30CrossRefGoogle Scholar
  6. 6.
    Newman J, Francis I, Kaminski M, Wahl RL. FDG-PET imaging in lymphoma: correlation with CT. Radiology 1994;190:111–116PubMedGoogle Scholar
  7. 7.
    Alavi JB, Alavi A, Chawluk J, Wahl RL. PET in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074–1078PubMedCrossRefGoogle Scholar
  8. 8.
    Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998;25:1261–1269PubMedCrossRefGoogle Scholar
  9. 9.
    Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992;33:532–536PubMedGoogle Scholar
  10. 10.
    Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567–575PubMedGoogle Scholar
  11. 11.
    Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371–388PubMedCrossRefGoogle Scholar
  12. 12.
    Huang SC, Williams BA, Barrio JR, Krivokapich J, Nissenson C, Hoffman EJ, et al. Measurement of glucose and 2-deoxy-2 [18F] fluoro-D-glucose transport and phosphorylation rates in myocardium using dual-tracer kinetic experiment. FEBS Lett 1987;216:128–132PubMedCrossRefGoogle Scholar
  13. 13.
    Mankoff D, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500–509PubMedGoogle Scholar
  14. 14.
    Wu HM, Bergsneider M, Glenn TC, Yeh E, Hovda DA, Phelps ME, et al. Measurement of the global lumped constant for 2-deoxy-2-[18F] fluoro-D-glucose in normal human brain using [15O] water and 2-deoxy-2 [18F] fluoro-D-glucose positron emission tomography imaging: a method with validation based on multiple methodologies. Mol Imaging Biol 2003;5:32–41PubMedCrossRefGoogle Scholar
  15. 15.
    Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002;29:443–453PubMedCrossRefGoogle Scholar
  16. 16.
    Ishikawa M, Kikuchi H, Nagata I. Glucose consumption and rate constants for 18F-fluorodeoxyglucose in human gliomas. Neurol Med Chir 1990;30:377–381CrossRefGoogle Scholar
  17. 17.
    Herholz K, Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol 1992;12:159–165PubMedCrossRefGoogle Scholar
  18. 18.
    Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Bernd L, Haberkorn U, Ewerbeck V, et al. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med 2004;45:1528–1535PubMedGoogle Scholar
  19. 19.
    Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006;33:164–168PubMedCrossRefGoogle Scholar
  20. 20.
    O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997;38:1575–1583PubMedGoogle Scholar
  21. 21.
    Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Shishido F, et al. Perfusion and metabolism in predicting the survival of patients with gliomas. Cancer 1994;73:2386–2394PubMedCrossRefGoogle Scholar
  22. 22.
    Terae S, Ogata A. Nonenhancing primary central nervous system lymphoma. Neuroradiology 1996;38:34–37PubMedCrossRefGoogle Scholar
  23. 23.
    Earnest F 4th, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166:823–827PubMedGoogle Scholar
  24. 24.
    Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323–1329PubMedGoogle Scholar
  25. 25.
    Wahl RL, Zasadny KR, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–2111PubMedGoogle Scholar
  26. 26.
    Romer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464–4471PubMedGoogle Scholar
  27. 27.
    Hautzel H, Muller-Gartner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997;38:1384–1386PubMedGoogle Scholar
  28. 28.
    Fischman AJ, Thornton AF, Frosch MP, Swearinger B, Gonzalez RG, Alpert NM. FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningioma. J Nucl Med 1997;38:1027–1029PubMedGoogle Scholar
  29. 29.
    Haberkorn U, Strauss LG, Dimitrakopoupou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of dluorodeoxy glucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485–1490PubMedGoogle Scholar
  30. 30.
    Gjedde A, Wienhard K, Heiss WD, Kloster G, Diemer NH, Herholz K, et al. Comparative regional analysis of 2-fluoro deoxyglucose and methyl glucose uptake in brain of four stroke patients with special reference to the regional estimation of the lumped constant. J Cereb Blood Flow Metab 1985;5:163–178PubMedGoogle Scholar
  31. 31.
    Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [11C]-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897–916PubMedCrossRefGoogle Scholar
  32. 32.
    Ogawa T, Kanno I, Hatazawa J, Inugami A, Fujita H, Shimosegawa E, et al. Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. RadioGraphics 1994;14:101–110PubMedGoogle Scholar
  33. 33.
    Pruim J, Willemsen ATM, Molenaar W, van Waarde A, Paans AM, Heesters MA, et al. Brain tumors: l-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 1995;197:221–226PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Yoshihiro Nishiyama
    • 1
  • Yuka Yamamoto
    • 1
  • Toshihide Monden
    • 1
  • Yasuhiro Sasakawa
    • 1
  • Nobuyuki Kawai
    • 2
  • Katashi Satoh
    • 1
  • Motoomi Ohkawa
    • 1
  1. 1.Department of Radiology, Faculty of MedicineKagawa UniversityKagawaJapan
  2. 2.Department of Neurosurgery, Faculty of MedicineKagawa UniversityKagawaJapan

Personalised recommendations